Drug Profile


Alternative Names: G-CSF; Gracinᵀᴹ; Gran; Granulocyte colony-stimulating factor - Amgen; Granulokine; Grasinᵀᴹ; KRN 8601; Meograstim; Neupogen; Nupen

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kirin-Amgen
  • Developer Amgen; Apricus Biosciences; Bristol-Myers Squibb; GlaxoSmithKline; Kirin Holdings Company; Kirin-Amgen; Kyowa Hakko Kirin; University of Washington
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chemotherapy-induced damage; Neutropenia; Radiation injuries
  • Phase I/II Breast cancer

Most Recent Events

  • 08 May 2017 Amgen terminates a phase I/II trial as the sponsor withdrew the study in Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (IV) (NCT00041470)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neutropenia in USA (Topical)
  • 23 Feb 2016 Kyowa Hakko Kirin Company and Asan Medical Center plan a phase II trial for Neutropenia (Prevention, in patients with breast cancer undergoing adjuvant chemotherapy) in South Korea (SC) (NCT02685111)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top